[18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancerRohini Sharma, Eric O. Aboagye, Michelle Chen et al.|European Journal of Nuclear Medicine and Molecular Imaging|2019Cited by 16
[<sup>18</sup>F] Fluciclatide PET as a biomarker of clinical response to combination therapy of pazopanib and paclitaxel in patients with platinum-resistant or platinum-refractory advanced ovarian cancer: Results of a phase Ib study.Rohini Sharma, Eric O. Aboagye, Pablo Oriol Valls et al.|Journal of Clinical Oncology|2019Cited by 1